Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgA2 (AM130)

Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgA2 (AM130) is a chimeric monoclonal antibody combining the constant domains of the human IgA2 molecule with mouse variable regions. The variable region was obtained from a mouse immunized with purified recombinant SARS-CoV-2 Spike S1 protein.

Product Specifications

Background

It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

CAS Number

9007-83-4

Host

HEK293

Origin Species

Mouse,Human

Target

Spike S1

Conjugation

Unconjugated

Tag

Human IgA2m1 | Human Kappa | C-10xHis

Stability

● -20°C to -70°C for 12 months in lyophilized state; ● -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles.

Purity

95%

Bioactivity

<strong>Detection of Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgA2 (AM130) titer by ELISA Assay.</strong><br> Immobilized SARS-CoV-2 S protein RBD, His Tag(Cat. No. SPD-C52H1) at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgA2 (AM130) (Cat. No. SPD-M521) with a linear range of 0.2-8 ng/mL (QC tested).